Susan Mesco | Pacira Pharmaceuticals, Inc. |
David M. Stack | Pacira Pharmaceuticals, Inc. |
Richard E. Scranton | Pacira Pharmaceuticals, Inc. |
Scott N. Braunstein | Pacira Pharmaceuticals, Inc. |
Charles A. Reinhart III | Pacira Pharmaceuticals, Inc. |
Randall S. Stanicky | RBC Capital Markets LLC |
Douglas Tsao | Barclays Capital, Inc. |
Tazeen Ahmad | Bank of America Merrill Lynch |
Michael E. Ingerman | Piper Jaffray & Co. |
Dana Flanders | Goldman Sachs & Co. LLC |
Chris Schott | JPMorgan Securities LLC |
Serge Belanger | Needham & Co. LLC |
Gary Nachman | BMO Capital Markets (United States) |
Good day, ladies and gentlemen, and welcome to the Pacira Pharmaceuticals' Fourth Quarter Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time.
As a reminder, this conference call is being recorded. I would now like to introduce your host for today's conference Head of Investor Relations, Susan Mesco.